What is the ApreMilast?

ApreMilast is , while it's Molecular Formula is C22H24N2O7S. Apremilast is an oral phosphodiesterase 4 inhibitor used in the treatment of adults with active psoriatic arthritis and adults with moderate to severe plaque psoriasis.

What is the CAS number for ApreMilast?

The CAS number of ApreMilast is 608141-41-9.

What is ApreMilast (608141-41-9) used for?

Apremilast is the first and only oral phosphodiesterase IV (PDE-4) inhibitor and anti-tumor necrosis factor alpha (TNFa) agentlaunched in the USA by Celgene for the treatment of active psoriaticarthritis (PsA). Apremilast was also approved for the treatmentof moderate to severe plaque psoriasis in the USA. Later,this drug was also approved in the European Union (EU) for bothindications. Although multiple approaches to the synthesis ofapremilast have been described, the most likely process scale approach involves the construction of the challenging stereogenicbenzylic carbon center by catalytic asymmetric hydrogenation.InChI:N-{2-[(1S)-1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide

Product Class

608141-41-9

Product Name：Apremilast
Molecular Formula：C₂₂H₂₄N₂O₇S
Purity：99%
Molecular Weight：460.508

Inquiry

Product Details:

CasNo： 608141-41-9

Molecular Formula： C₂₂H₂₄N₂O₇S

Factory Supply High Purity 99% Pure Apremilast 608141-41-9 Safe Shipping

Molecular Formula:C22H24N2O7S
Molecular Weight:460.508
Boiling Point:741.342 °C at 760 mmHg
PKA:14.01±0.20(Predicted)
Flash Point:402.149 °C
PSA：127.46000
Density:1.382 g/cm³
LogP:3.52590

ApreMilast(Cas 608141-41-9) Usage

Description	Apremilast, marketed under the brand name Otezla, is a medication approved by the FDA for the treatment of certain types of psoriasis, psoriatic arthritis, and ulcers in the mouth associated with Behcet's syndrome. It belongs to a class of oral small molecule inhibitors known as phosphodiesterase 4 (PDE4) inhibitors.
Indications	Apremilast is used for the treatment of active psoriatic arthritis in adults. It is also employed for the management of moderate to severe plaque psoriasis in certain patients.
Uses	Apremilast is indicated for the treatment of adult patients with active psoriatic arthritis. Apremilast helps improve skin symptoms, including redness, scaling, and thickness caused by plaque psoriasis.
FDA Approval	Apremilast received FDA approval on March 21, 2014, for the treatment of adult patients with active psoriatic arthritis. It is also approved for use in adults with plaque psoriasis who are candidates for phototherapy or systemic therapy, as well as adults with Behcet's disease associated with oral ulcers.

InChI:N-{2-[(1S)-1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide

608141-41-9 Relevant articles

Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial

Dr Kim Papp, MD Jennifer C Cather, MD Les Rosoph, MD Howard Sofen, MD Richard G Langley, MD Robert T Matheson, MD

, The Lancet, VOLUME 380, ISSUE 9843, P738-746, AUGUST 25, 2012

At week 16, patients in the placebo group were assigned apremilast 20 or 30 mg twice daily until week 24. Randomisation was generated with a permuted-block randomisation list via interactive voice response system. For the first 16 weeks, treatment assignment was concealed from both investigators and participants.

Chemoenzymatic synthesis of apremilast: A study using ketoreductases and lipases

Vega, Kimberly B.,Cruz, Daniel M. V.,Oliveira, Artur R. T.,Da Silva, Marcos R.,De Lemos, Telma L. G.,Oliveira, Maria C. F.,Bernardo, Ricardo D. S.,De Sousa, Jackson R.,Zanatta, Geancarlo,Nasário, Fábio D.,Marsaioli, Anita J.,De Mattos, Marcos C.

, p. 1100 - 1110 (2021/05/19)

The key step in the chemoenzymatic synth...

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis

Ejaz Pathan1, Sonya Abraham2, Elizabeth Van Rossen3, Robin Withrington3, Andrew Keat4, Peter J Charles1, Erin Paterson1, Muslima Chowdhury1, Catherine McClinton5, Peter C Taylor5

Annals of the Rheumatic Diseases, Volume 72, Issue 9

In this double-blind, placebo-controlled, single-centre, Phase II study, patients with symptomatic AS with active disease on MRI were randomised to apremilast 30 mg BID or placebo over 12 weeks. Bath Indices were monitored serially. Patients were followed for 4 weeks after stopping medication. Bone biomarkers were assessed at baseline and day 85.

608141-41-9 Upstream products

6296-53-3
3-acetylaminophthalic anhydride
608141-43-1
(S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethanamine-(S)-2-acetamido-4-methylpentanoate
608141-42-0
(S)-2-[1 (3-ethoxy-4-methoxyphenyl)]-1-methanesulfonyl-2-ethylamine
1450657-31-4
1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethen-1-amine

608141-41-9 Downstream products

1384967-20-7
(S)-N-{2-[1-(3-hydroxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}-acetamide
1384441-38-6
(S)-N-(2-(1-(3-ethoxy-4-hydroxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide
1384439-79-5
(S)-N-{2-[1-(3,4-dihydroxy-phenyl)-2-methanesulfonyl-ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}-acetamide
1384967-21-8
(2S,3R,4S,5S,6S)-2-(4-((S)-1-(4-acetamido-1,3-dioxoisoindolin-2-yl)-2-(methylsulfonyl)ethyl)-2-ethoxyphenoxy)-6-((benzyloxy)carbonyl)tetrahydro-2H-pyran-3,4,5-triyltriacetate

Relevant Products

Sparsentan
CAS：254740-64-2
2'-Chloro acetophenone
CAS：2142-68-9
Etrasimod
CAS：1206123-37-6